North America and Europe Skin Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Melanoma and Non-melanoma), Screening Type (Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy)
The North America and Europe skin cancer diagnostics market is projected to reach US$ 3,730.12 million by 2028 from US$ 2,309.60 million in 2021; it is expected to grow at a CAGR of 7.1% from 2021 to 2028.
Skin cancer means abnormal growth of skin cells. It develops in the areas exposed to the sun. Ultraviolet radiation changes the genetic material (DNA) in cells and is the leading cause of skin cancer. Skin cancer is the most common form of cancer. There are two main categories of skin cancer such as melanoma and non-melanoma. Various imaging solutions such as CT scans, MRIs, PET scans, bone scans, and chest X-rays are used to diagnose skin cancer. The skin cancer diagnostics market also includes various diagnostics and therapies related to skin cancer, such as chemotherapy, targeted therapy, immunotherapy, radiotherapy, freezing treatment, and scraping therapy that helps cure skin cancer.
The North America and Europe skin cancer diagnostics market is segmented on the bases of type, screening type, and geography. By geography, the market is broadly segmented into North America and Europe. The report offers insights and in-depth analysis of the market, emphasizing on parameters such as market trends, technological advancements, and market dynamics along with the analysis of competitive landscape of world’s leading market players.
Market Insights
Increasing Incidence of Skin Cancer Drives the Skin Cancer Diagnostics Market Growth
According to the World Health Organization (WHO), in 2020, cancer accounted for 10 million deaths worldwide. Breast, lung, colon and rectum, prostate, skin, and stomach cancer were the commonly seen types in the world in that year. According to the WHO data, ~1.20 million of the new cases reported in 2020 were skin cancer cases. Skin cancer is by far the most common of all cancer types. Melanoma and non-melanoma are the two types of skin cancer. Although melanoma accounts for ~1% of total skin cancer cases, it causes maximum skin cancer deaths. According to the Skin Cancer Foundation, during 2012–2022, annual diagnosis for invasive melanoma cases increased by 31%. As per GLOBOCAN 2020, worldwide 19.3 million new cancer cases, excluding 18.1 million nonmelanoma skin cancer cases, were registered in 2020. Several countries have adopted national programs for cancer awareness and early cancer diagnosis. Furthermore, increased exposure of people to ultraviolet rays leads to genetic mutations, which may cause skin cancer in the long term. The growing awareness about such aspects drives the skin cancer diagnostics market growth.
Launch of New Products Contributes Significantly to Market Growth
The need for the timely diagnosis of skin cancer boosts the demand for better and advanced diagnosis solutions. In response to such prominent demand, various companies focus on offering better products for the diagnosis of skin cancer. In January 2020, 3Derm Systems, Inc. received two FDA Breakthrough Device designations for its 3DermSpot. 3DermSpot is an AI-based algorithm that autonomously detects melanoma, squamous cell carcinoma, and basal cell carcinoma using standardized skin images saved in it. In May 2021, this device was awarded a breakthrough device designation by the FDA. Presently, the company is awaiting to receive FDA approval for its commercial launch in the US.
In May 2021, SciBase Holding AB launched its Non-Melanoma Skin Cancer (NMSC) clinical application (app) and MDR certification process. The NMSC application is designed to support the company’s Nevisense technology platform. The Nevisense, which helps detect melanoma, is a CE-marked device available in Europe; moreover, it has received the TGA and FDA approvals for commercial use in the US, respectively. The company is looking forward to integrating the NMSC clinical application into its Nevisense 3.0 version. In December 2021, Foundation Medicine, Inc. received FDA approval for its FoundationOneCDx. The FoundationOneCDx is a next-generation sequencing-based in-vitro diagnostic device. It is FDA approved therapeutics in melanoma for present and future. It is enabled with the BRAF inhibitor monotherapies targeting the BRAFV600E mutations and BRAF/MEK inhibitor combination therapies targeting the BRAFV600E or V600K mutations. It is considered an important step toward enabling simplified decision-making for oncologists.
Such innovations by cancer diagnostics companies are driving the North America and Europe skin cancer diagnostics market growth.
Type Insights
Based on type, the North America and Europe skin cancer diagnostics market is segmented into melanoma and non-melanoma. The non-melanoma segment held the largest share of the market in 2021. Moreover, the market for the non-melanoma segment is expected to grow at the highest CAGR during 2021–2028. Non-melanoma skin cancers are more frequent than melanoma skin cancer. These are completely curable through surgery and are rarely lethal, however, surgical treatment is painful and disfiguring. According to the Skin Cancer Foundation, it is stated that over 5, 400 people globally die of non-melanoma skin cancer every month. Various countries across the world are raising awareness with respect to non-melanoma skin cancer. For instance, in June 2019, The European Cancer Patient Coalition (ECPC) and the European Academy of Dermatology and Venereology (EADV) has launched the Global Non-Melanoma Skin Cancer (NMSC) Awareness Day to raise awareness of NMSC.
Screening Type Insights
Based on screening type, the North America and Europe skin cancer diagnostics market is segmented into blood tests, dermatoscopy, imaging tests, lymph node biopsy, and skin biopsy. The skin biopsy segment held the largest market share in 2021, and it is further expected to be the largest shareholder in the market by 2028. Skin biopsy is diagnosis procedure that require a small sample of the skin. It is performed to determine skin cancer, infection or other skin conditions. These types of biopsies are performed for melanoma skin cancer. And in cases of non-melanoma, biopsy is often the only test done to diagnose the stage or the extension of the cancer as non-melanoma skin cancer rarely spreads. The increasing awareness and incidences of skin cancer are likely to drive the North America and Europe skin cancer diagnostics market during the forecast period.
Skin Cancer Diagnostics Market, by Type – 2021 and 2028
Get more information on this report :
Strategic Insights
Product launches, and mergers and acquisitions are the highly adopted strategies by the players operating in the North America and Europe skin cancer diagnostics market. A few of the recent key product developments are listed below:
In August 2020, Michelson Diagnostics Ltd. had announced the launch of VivoTools, an advanced software suite for the analysis of VivoSight Dx OCT images. VivoSight Dx isone of the leading Optical Coherence Tomography (OCT) skin imaging system which can see over 1 mm deep into the skin to produce images of skin structural elements, vascularity and pathology. The company have made a couple of significant advances to the image analysis software, resulting in the debut of a new brand, called VivoTools.
In December 2021, BioIQ, Inc. and DermTech, Inc. has collaborated to bring increased patient access to precision genomics. The DermTech Melanoma Test is now included in BioIQ's lineup of testing options for employee and member health programs.
In December 2021, SkylineDx had announced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics. The collaboration aims to progress high potential research projects into in vitro diagnostic device (IVD) development trajectories to create commercially viable products linked to unmet medical needs for global markets.
The COVID-19 pandemic also has a substantial impact on diagnostics in the regions due to the closure of practices. The COVID-19 pandemic has radically changed clinical and surgical routines, profoundly impacting all aspects of healthcare and surgical practice, from the workforce and prioritization of procedures to the risk of viral disease and intraoperative transmission. According to a research article published in March 2021, universal healthcare claims in Ontario showed drastic drop in total skin biopsies. There was 15% drop in biopsies from the expected rate. There were huge backlogs in skin biopsies during the lockdown. The UK healthcare system has been severely affected by the COVID-19 pandemic. The UK healthcare system, including skin cancer departments, has been hit hard by the COVID-19 pandemic. Thus, the pandemic has negatively impacted the market for skin cancer diagnosis. However, the reopening of all medical services are expected to increase the demand for skin cancer diagnosis further leading to vital market growth.
Skin Cancer Diagnostics – Market Segmentation
The skin cancer diagnostics market is segmented on the basis of type, and screening type. Based on type, the market is segmented into melanoma and non-melanoma. By screening type, the skin cancer diagnostics market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests. By geography, the market is segmented into North America (the US, Canada, and Mexico) and Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe).
Company Profiles
- SkylineDx BV
- AMLo Biosciences Limited
- NeraCare GmbH
- DermLite LLC
- F. HOFFMANN-LA ROCHE LTD
- bioMerieux SA
- Veriskin Inc.
- Castle Biosciences, Inc.
- DermTech Inc
- Michelson Diagnostics Ltd.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Skin Cancer Diagnostics Market – By Type
1.3.2 Global Skin Cancer Diagnostics Market – By Screening Type
1.3.3 Global Skin Cancer Diagnostics Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Skin Cancer Diagnostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America– PEST Analysis
4.2.2 Europe– PEST Analysis
4.3 Expert Opinion
5. Skin Cancer Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Incidence of Skin Cancer
5.1.2 Launch of New Skin Cancer Diagnostics Products
5.2 Market Restraints
5.2.1 Barriers to Early Skin Cancer Diagnostics in Low and Middle-Income Countries
5.3 Market Opportunities
5.3.1 Government Support for Early Skin Cancer Diagnosis
5.4 Future Trends
5.4.1 Skin Cancer Diagnostics Through AI
5.5 Impact Analysis
6. Skin Cancer Diagnostics Market – Global Analysis
6.1 Global Skin Cancer Diagnostics Market Revenue Forecast and Analysis
6.2 Global Skin Cancer Diagnostics Market Revenue Forecast and Analysis
6.3 Market Positioning of Key Players
7. Skin Cancer Diagnostics Market Analysis – By Type
7.1 Overview
7.2 Skin Cancer Diagnostics Market Revenue Share, by Type (2021 and 2028)
7.3 Melanoma
7.3.1 Overview
7.3.2 Melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Non-melanoma
7.4.1 Overview
7.4.2 Non-melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8. Skin Cancer Diagnostics Market – By Screening Type
8.1 Overview
8.2 Skin Cancer Diagnostics Market, by Screening Type, 2021 and 2028 (%)
8.3 Blood Tests
8.3.1 Overview
8.3.2 Blood Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Dermatoscopy
8.4.1 Overview
8.4.2 Dermatoscopy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Imaging Tests
8.5.1 Overview
8.5.2 Imaging Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Lymph Node Biopsy
8.6.1 Overview
8.6.2 Lymph Node Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Skin Biopsy
8.7.1 Overview
8.7.2 Skin Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9. Skin Cancer Diagnostics Market – Regional Analysis
9.1 North America: Skin Cancer Diagnostics Market
9.1.1 Overview
9.1.2 North America: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.3 North America: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.4 North America: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ Million)
9.1.5 North America: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
9.1.5.1 US: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.1.1 US: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.1.2 US: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.5.1.3 US: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.1.5.2 Canada: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.2.1 Canada: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.2.2 Canada: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.5.2.3 Canada: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.1.5.3 Mexico: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.3.1 Mexico: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.3.2 Mexico: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.5.3.3 Mexico: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.2 Europe: Skin Cancer Diagnostics Market
9.2.1 Overview
9.2.2 Europe: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.3 Europe: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.4 Europe: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5 Europe: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
9.2.5.1 Germany: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.1 Overview
9.2.5.1.2 Germany: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.3 Germany: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.1.4 Germany: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.2 United Kingdom: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.1 Overview
9.2.5.2.2 United Kingdom: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.3 United Kingdom: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.2.4 United Kingdom: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.3 France: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.1 Overview
9.2.5.3.2 France: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.3 France: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.3.4 France: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.4 Italy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.1 Overview
9.2.5.4.2 Italy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.3 Italy: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.4.4 Italy: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.5 Spain: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.1 Overview
9.2.5.5.2 Spain: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.3 Spain: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.5.4 Spain: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
9.2.5.6 Rest of Europe: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.1 Overview
9.2.5.6.2 Rest of Europe: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.3 Rest of Europe: Skin Cancer Diagnostics Market, by Type- 2019–2028 (US$ Million)
9.2.5.6.4 Rest of Europe: Skin Cancer Diagnostics Market, by Screening Type- 2019–2028 (US$ Million)
10. Impact of COVID-19 Pandemic on Global Skin Cancer Diagnostics Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
11. Skin Cancer Diagnostic Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Skin Cancer Diagnostic Market (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 SkylineDx BV
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 SWOT Analysis
12.1.5 Key Developments
12.2 AMLo Biosciences Limited
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 SWOT Analysis
12.2.5 Key Developments
12.3 NeraCare GmbH
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 SWOT Analysis
12.3.5 Key Developments
12.4 DermLite LLC
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 bioMerieux SA
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Veriskin Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Castle Biosciences, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 DermTech Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 HOFFMANN-LA ROCHE LTD.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.10 Michelson Diagnostics Ltd.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 2. North America: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. US: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 4. US: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 5. Canada: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 6. Canada: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 7. Mexico: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 8. Mexico: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 9. Europe Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 10. Europe Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 11. Germany Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. Germany Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 13. United Kingdom Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. United Kingdom Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 15. France Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 16. France Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 17. Italy Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. Italy Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 19. Spain Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 20. Spain Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of Europe Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Europe Skin Cancer Diagnostics Market, by Screening Type– Revenue and Forecast to 2028 (US$ Million)
Table 23. Organic Developments in the Skin Cancer Diagnostic Market
Table 24. Inorganic Developments in the Skin Cancer Diagnostics Market
Table 25. Glossary of Terms, Skin Cancer Diagnostics Market
LIST OF FIGURES
Figure 1. Skin Cancer Diagnostics Market Segmentation
Figure 2. Skin Cancer Diagnostics Market, By Region
Figure 3. Global Skin Cancer Diagnostics Market Overview
Figure 4. Non-Melanoma Segment Held Largest Share of Type Segment in Skin Cancer Diagnostics Market
Figure 5. North America is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Skin Cancer Diagnostics Market, by Geography (US$ Million)
Figure 7. Global Skin Cancer Diagnostics Market- Leading Country Markets (US$ Million)
Figure 8. Global Skin Cancer Diagnostics Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Skin Cancer Diagnostics Market Impact Analysis of Driver and Restraints
Figure 12. Global Skin Cancer Diagnostics Market– Revenue Forecast and Analysis – 2020- 2028
Figure 13. Global Skin Cancer Diagnostics Market– Revenue Forecast and Analysis – 2021 - 2028
Figure 14. Market Positioning of Key Players in Global Skin Cancer Diagnostics Market
Figure 15. Skin Cancer Diagnostics Market Revenue Share, by Type (2021 and 2028)
Figure 16. Melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Non-melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Skin Cancer Diagnostics Market, by Screening Type, 2021 and 2028 (%)
Figure 19. Blood Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Dermatoscopy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Imaging Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Lymph Node Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Skin Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. North America: Skin Cancer Diagnostics Market, by Key Country – Revenue (2021) (US$ ‘Million)
Figure 25. North America: Skin Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ ‘Million)
Figure 26. North America: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 27. US: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 28. Canada: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 29. Mexico: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 30. Europe: Skin Cancer Diagnostics Market, by Key Country – Revenue (2021) (US$ Million)
Figure 31. Europe Skin Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
Figure 32. Europe: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 33. Germany: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. United Kingdom: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. France: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Italy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Spain: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Rest of Europe: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Impact Of COVID-19 Pandemic in North American Country Markets
Figure 40. Impact of COVID-19 Pandemic in European Country Markets
Figure 41. Growth Strategies in the Skin Cancer Diagnostic Market (%)
- SkylineDx BV
- AMLo Biosciences Limited
- NeraCare GmbH
- DermLite LLC
- bioMerieux SA
- Veriskin Inc.
- Castle Biosciences, Inc.
- DermTech Inc.
- HOFFMANN-LA ROCHE LTD.
- Michelson Diagnostics Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America and Europe skin cancer diagnostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America and Europe skin cancer diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America and Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.